96 related articles for article (PubMed ID: 23880334)
1. Developing an in situ nanosuspension: a novel approach towards the efficient administration of poorly soluble drugs at the anterior eye.
Luschmann C; Tessmar J; Schoeberl S; Strauss O; Framme C; Luschmann K; Goepferich A
Eur J Pharm Sci; 2013 Nov; 50(3-4):385-92. PubMed ID: 23880334
[TBL] [Abstract][Full Text] [Related]
2. Ocular delivery systems for poorly soluble drugs: an in-vivo evaluation.
Luschmann C; Herrmann W; Strauss O; Luschmann K; Goepferich A
Int J Pharm; 2013 Oct; 455(1-2):331-7. PubMed ID: 23867983
[TBL] [Abstract][Full Text] [Related]
3. Self-assembling colloidal system for the ocular administration of cyclosporine A.
Luschmann C; Tessmar J; Schoeberl S; Strauß O; Luschmann K; Goepferich A
Cornea; 2014 Jan; 33(1):77-81. PubMed ID: 24162754
[TBL] [Abstract][Full Text] [Related]
4. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
[TBL] [Abstract][Full Text] [Related]
5. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results.
Gan L; Gan Y; Zhu C; Zhang X; Zhu J
Int J Pharm; 2009 Jan; 365(1-2):143-9. PubMed ID: 18773948
[TBL] [Abstract][Full Text] [Related]
6. Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
Dutescu RM; Panfil C; Merkel OM; Schrage N
Eur J Pharm Biopharm; 2014 Sep; 88(1):123-8. PubMed ID: 24844949
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods.
Kim JH; Jang SW; Han SD; Hwang HD; Choi HG
Pharmazie; 2011 Jul; 66(7):491-5. PubMed ID: 21812323
[TBL] [Abstract][Full Text] [Related]
8. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
[TBL] [Abstract][Full Text] [Related]
9. In vivo tissue distribution and efficacy studies for cyclosporin A loaded nano-decorated subconjunctival implants.
Yavuz B; Bozdağ Pehlivan S; Kaffashi A; Çalamak S; Ulubayram K; Palaska E; Çakmak HB; Ünlü N
Drug Deliv; 2016 Nov; 23(9):3279-3284. PubMed ID: 27027148
[TBL] [Abstract][Full Text] [Related]
10. Combination of PEGylation and Cationization on Phospholipid-Coated Cyclosporine Nanosuspensions for Enhanced Ocular Drug Delivery.
Ma X; Liu Y; Wang J; Liu H; Wei G; Lu W; Liu Y
ACS Appl Mater Interfaces; 2024 May; 16(21):27040-27054. PubMed ID: 38743443
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine A Nanosuspensions for Ophthalmic Delivery: A Comparative Study between Cationic Nanoparticles and Drug-Core Mucus Penetrating Nanoparticles.
Yan R; Xu L; Wang Q; Wu Z; Zhang H; Gan L
Mol Pharm; 2021 Dec; 18(12):4290-4298. PubMed ID: 34731571
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
Aksungur P; Demirbilek M; Denkbaş EB; Vandervoort J; Ludwig A; Unlü N
J Control Release; 2011 May; 151(3):286-94. PubMed ID: 21241752
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin nanosphere formulation for ophthalmic administration.
Khan W; Aldouby YH; Avramoff A; Domb AJ
Int J Pharm; 2012 Nov; 437(1-2):275-6. PubMed ID: 22951866
[TBL] [Abstract][Full Text] [Related]
14. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs.
Agarwal P; Scherer D; Günther B; Rupenthal ID
Int J Pharm; 2018 Mar; 538(1-2):119-129. PubMed ID: 29339249
[TBL] [Abstract][Full Text] [Related]
15. A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation.
Di Tommaso C; Valamanesh F; Miller F; Furrer P; Rodriguez-Aller M; Behar-Cohen F; Gurny R; Möller M
Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):2292-9. PubMed ID: 22427552
[TBL] [Abstract][Full Text] [Related]
16. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution.
Tam JM; McConville JT; Williams RO; Johnston KP
J Pharm Sci; 2008 Nov; 97(11):4915-33. PubMed ID: 18351641
[TBL] [Abstract][Full Text] [Related]
17. Ocular distribution of cyclosporin A (Sandimmun) following systemic and topical administration to rabbits.
Vernillet L; Lundh RL; Acezat-Mispelter F; Goizel C; Humbert H; Pouliquen Y
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():150-8. PubMed ID: 1820870
[TBL] [Abstract][Full Text] [Related]
18. A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation.
Pınar SG; Canpınar H; Tan Ç; Çelebi N
Eur J Pharm Sci; 2022 Apr; 171():106123. PubMed ID: 35017012
[TBL] [Abstract][Full Text] [Related]
19. Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study.
Le Bourlais CA; Chevanne F; Turlin B; Acar L; Zia H; Sado PA; Needham TE; Leverge R
J Microencapsul; 1997; 14(4):457-67. PubMed ID: 9229345
[TBL] [Abstract][Full Text] [Related]
20. Poorly water-soluble drug nanoparticles via solvent evaporation in water-soluble porous polymers.
Roberts AD; Zhang H
Int J Pharm; 2013 Apr; 447(1-2):241-50. PubMed ID: 23499755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
